Nutra Pharma Files Provisional Patent for Nerve Agent Counter Measures
Contact: Nutra Pharma Corp. Nina Goldstein 877-895-5647 IR@nutrapharma.com February 21, 2018 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have filed a new provisional patent
Nutra Pharma Announces Nyloxin® Distribution Agreement for Australia and New Zealand
Contact: Nutra Pharma Corp. Nina Goldstein 877-895-5647 IR@nutrapharma.com February 1, 2018 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis (MS) and HIV and that also markets the over-the-counter (OTC) pain drugs; Nyloxin® and Pet Pain-Away™, announced today that they have signed a definitive Distribution Agreement with the Australian company, Pharmachal PTY LTD to market and d